Altre lingue Chugai Pharmaceutical Co., Ltd

Azioni

4519

JP3519400000

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 16/04/2024			Variaz. 5gg	Var. 1 gen.
5.131 ^JPY	+0,51%		-4,95%	-3,95%

10/04	Il Nikkei giapponese scivola sulla cautela in vista dei dati sull'inflazione negli Stati Uniti	RE
29/03	Chugai Pharmaceutical assegnerà 594 milioni di yen di azioni proprie come compensazione di azioni vincolate	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks	15/04
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan	10/04
MÄRKTE ASIEN/Uneinheitlich vor US-Inflationsdaten - Hongkong deutlich im Plus	10/04
Japan's Nikkei slips on caution ahead of US inflation data	10/04
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	29/03
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer	28/03
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan	28/03
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion	27/03
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials	27/03
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan	27/03
Roche's Chugai Wins Japanese Approval for Piasky Injection	27/03
Chugai Pharmaceutical : Finance Report (Jan-Dec 2023) (Posted on March 28)	25/03
MIDDAY BRIEFING - Unternehmen und Märkte	22/03
Roche: échec d'une étude avec Enspryng contre la myasthénie grave généralisée	21/03
Argenx flink in de lift	21/03
Les actions en mouvement : ArgenX peut remercier Chugai, Esso flambe	21/03
Roche-Tochter Chugai erreicht in Phase-III-Studie mit Enspryng Ziele nicht	21/03
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors	01/03
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	26/02
Point marchés-L'Europe attendue en consolidation avant une salve de données	26/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Chugai Pharmaceutical Co., Ltd

Azioni

4519

JP3519400000

Altre lingue

Filtri